From research to patient access
Psychedelic therapies are moving from clinical trials toward healthcare systems — but the path is complex. We break down the science, regulations, economics, and barriers shaping how these treatments reach the people who need them, with a focus on Europe and the United States.
The Big Picture
Landscape overview of psychedelic therapy implementation, key takeaways, and future outlook across Europe and the US.
Critical Observations from Collaborators
The integration of psychedelic therapies into European healthcare systems represents a complex challenge that extends beyond the scope of traditional...
Introduction to Psychedelics and Reimbursement
Psychedelic substances have been used for millennia in various indigenous cultures for religious, spiritual, and healing purposes. For instance,...
Reimbursement Pathways for Psychedelic Therapies: An Overview
Mental health disorders impose a severe and growing societal and economic burden across Europe. Both national governments and the European Union (EU) now...
The Science
Drug development stages, clinical trial phases, and the evidence base underpinning psychedelic therapies.
Regulatory Pathways
Approval processes, regulatory frameworks, and how different regions are approaching psychedelic therapy authorization.
Who Pays
Health economics, health technology assessment, reimbursement models, and insurance coverage for psychedelic therapies.
Payer Evidence Checklist for Psychedelic Therapies
What payers and HTA bodies need before psychedelic therapies can move from promising clinical evidence to coverage decisions.
The Personnel-Hours Question in Psychedelic Therapy
An evidence-first guide to supervised staff-hours in psychedelic therapy, and why protocol design, role mix, and regional systems shape cost and access.
Psychedelic Therapy Access in Europe: Comparison
Compare ketamine and esketamine licensing, reimbursement, and patient access pathways across selected European markets.
EU and UK HTA in 2026: Implications for reimbursement readiness
How EU HTA implementation and UK methods updates affect reimbursement strategy for psychedelic interventions.
Payer and Health Technology Assessments
Securing access to psychedelic therapies requires working with payers and health technology assessment (HTA) bodies after regulatory approval. These...
Reimbursement Landscape in Europe
In Europe, while the European Medicines Agency (EMA) handles drug approvals centrally for most countries, each country makes its own decisions about...
Barriers & Challenges
Stigma, supply chain constraints, training requirements, and political hurdles standing in the way of implementation.
Solutions & Models
Innovative approaches, therapy delivery models, and policy recommendations for advancing psychedelic therapy access.
PsyPal 2026: What the guidance changes for implementation strategy
A practical synthesis of the 2026 PsyPal guidance paper for implementation and access strategy in Europe and the UK.
Potential Reimbursement and Access Pathways
As psychedelic therapies move closer to approval in Europe, healthcare systems face a crucial question: How will patients access these treatments? The path...
Solutions and Recommendations
This chapter explores practical solutions for integrating psychedelic therapies into European healthcare systems. Building on the previous chapter's...
Access & Equity
Global access considerations, underserved populations, equitable distribution, and emerging pathways to broad availability.
Comparative access pathways: Oregon, Canada and Australia
A comparative implementation summary of access pathways in Oregon, Canada and Australia, with practical implications for equity and scale.
Ensuring Equitable Access
As psychedelic therapies move closer to approval and implementation across Europe, ensuring fair and equal access becomes a critical challenge. Early...